Use of Oral Anticoagulation in a Real-World Population With Device Detected Atrial Fibrillation.

ABSTRACT: Background Guideline recommendations for oral anticoagulation (OAC) in patients with atrial fibrillation (AF) are based on CHA₂DS₂-VASc score alone. Patients with cardiac implantable electronic devices provide an opportunity to assess how the interaction between AF duration and CHA₂DS₂-VASc score influences OAC prescription rates. Methods and Results Data from the Optum de-identified Electronic Health Record data set were linked to the Medtronic CareLink database of cardiac implantable electronic devices. An index date was assigned as the later of 6 months after device implant or 1 year after Electronic Health Record data availability. Maximum daily AF duration (no AF, 6 minutes-23.5 hours, and >23.5 hours) was assessed for 6 months before index

SUBMITTER: Kaplan RM 

PROVIDER: S-EPMC7955365 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature